A Mayo Clinic study shows that delivering chemotherapy at home is safe and feasible, reducing physical, emotional, and financial burdens associated with cancer treatment. Patients experienced fewer disruptions to daily life while maintaining a continuous connection with their care team through virtual visits and remote monitoring.
Researchers developed a targeted genetic therapy using milk-derived nanoparticles to attack cancer cells while sparing healthy tissue. The approach shows promise in treating aggressive bile duct cancer with limited treatment options.
The Mayo Clinic team developed a quantum-powered model that can detect movement intention from brain activity, potentially helping people with paralysis. The achievement marks one of Mayo Clinic's first end-to-end clinical applications of quantum computing.
Researchers identified a drug-and-supplement combination therapy that reduces senescent cells, inflammation, and injury in diabetic kidney disease. The treatment approach involves senolytics, which selectively target senescent cells.
Mayo Clinic researchers have identified a hidden 'movement map' deep within the brain, which could help surgeons reduce side effects from epilepsy procedures and guide future treatments for speech and movement disorders. The discovery was made using advanced brain-recording technology to create individualized maps of patients' brains.
A Mayo Clinic study found that women with abnormal Parkinson's-related protein levels accumulate Alzheimer's-related pathology faster, leading to faster disease progression. The study analyzed data from 415 participants and showed that women's brains progress up to 20 times faster than men's in this regard.
Researchers identified specific DNA-level changes in AD brains that affect oligodendrocyte function and tau protein levels. The study's findings may open new avenues for understanding neurodegenerative diseases and developing future therapies.
A Mayo Clinic study found that a single dose of non-prescribed Adderall can have measurable cardiovascular effects in healthy young adults, including significant increases in blood pressure and heart rate. The study highlights the risks of unsupervised use of stimulants like Adderall.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
Dr. Eric Moore, M.D., has been elected as a member of the Mayo Clinic Board of Trustees, bringing his extensive experience in head and neck surgery to guide strategic priorities. He is also a pioneer in less invasive transoral robotic surgery and has improved outcomes for patients with head and neck cancers.
Mayo Clinic has been ranked as the No. 1 hospital in the world for its eighth consecutive year by Newsweek, based on patient survey results and key performance metrics. The organization is transforming healthcare through its Bold. Forward. strategy, which combines deep clinical expertise with responsible digital innovation.
A Mayo Clinic study found that the brain enters a deep sleep state after a seizure, mimicking memory storage and strengthening disease. This phenomenon, called seizure-related consolidation, could help explain why epilepsy worsens over time and why memory and mood problems are common in people with the condition.
The collaboration will utilize Mayo Clinic Platform's secure infrastructure to analyze de-identified patient data from both institutions, enhancing research and driving innovation in healthcare. With access to over 15 million patients, the partnership aims to predict illness earlier, improve outcomes, and deliver more proactive care.
The Mayo Clinic Representative Office in the Cayman Islands will help patients make appointments at Mayo Clinic locations worldwide. The staff also assist with travel arrangements, billing, and insurance coordination, providing free services to patients and their families.
Researchers found that regulatory T cells can be redirected to protect tumors instead of the body. Blocking P2RX7, a molecule released by stressed cells, helps immune cells work more closely with B cells and leads to better outcomes.
The collaboration aims to integrate Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities to support drug discovery and development. The partnership will focus on high-need therapeutic areas, leveraging multimodal data sets and advanced analytics to advance progress in disease treatment.
The Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US. This innovative technology uses heat to damage and kill cancer cells, offering a new angle in cancer treatment and potentially improving outcomes for patients with resistant tumors.
A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Men who took oxybutynin also reported improvements in day-to-day functioning and overall quality of life.
Researchers discovered that combining brigatinib with PARP inhibitors is more effective in killing ovarian cancer cells by blocking their survival response. Brigatinib targets key signaling molecules FAK and EPHA2, which aggressive ovarian cancer cells rely on to survive.
The two organizations are expanding their collaboration to improve care for neurodegenerative disease, prostate cancer, and metastatic liver tumors through enhanced imaging and interventional technologies. This expanded partnership aims to bring more precise, less invasive, and personalized treatment approaches to patients.
The integration of OMOP Oncology into Mayo Clinic Platform enables faster analysis of complex cancer data, unlocking deeper insights and accelerating research. This expansion supports the development of next-generation therapies for patients worldwide.
Researchers found that when pancreatic tumors touch the superior mesenteric vein, patients who undergo surgery first experience reduced survival rates. In contrast, those who receive chemotherapy before surgery have similar survival outcomes to those with non-vein touching tumors. The study suggests reclassifying tumors based on vein i...
Researchers developed a gene-editing therapy that directly corrects genetic mutations responsible for autosomal dominant polycystic kidney disease, slowing cyst growth and improving health outcomes. The therapy uses CRISPR-based base editing to precisely correct single-letter DNA mutations in the PKD1 gene.
A global study of 17,494 people from 158 countries reveals a significant gap between expected and experienced perimenopause symptoms. Fatigue, mood changes, and sleep-related issues are the most common reported symptoms, with exhaustion and fatigue being particularly prevalent.
A new study published in The Lancet Obstetrics, Gynaecology, & Women's Health found that postmenopausal women receiving hormone therapy lost 35% more weight while taking tirzepatide, a GLP-1-based obesity medication. This research could help develop personalized strategies for managing cardiometabolic risk in postmenopausal women.
Researchers used CT scans and AI to find links between poorer abdominal muscle measures and higher incidence of falls in middle-aged adults. Maintaining good core strength throughout adulthood may provide benefits that start in midlife and continue into older adulthood.
A new oral contrast agent significantly improves visualization of inflammatory bowel disease (IBD) or cancer within the abdomen, according to clinical trial data. The dark borosilicate agent reveals previously impossible-to-detect findings, including small bowel tumors and subtle inflammatory conditions.
A new study from Mayo Clinic introduces MedEduChat, an EHR-integrated AI agent providing accurate and patient-specific prostate cancer education. The tool delivers clear explanations based on each patient's health record, improving confidence and understanding of diagnosis and treatment options.
Mayo Clinic researchers developed an AI-ECG model that accurately diagnoses advanced chronic liver disease, allowing for early intervention and potential lifesaving treatment. The study found the model detected twice as many cases as standard methods, highlighting the promise of AI in preventive care.
A new multicenter study led by Mayo Clinic researchers has established a practical definition for rapidly progressive dementia (RPD), a rare but devastating form of cognitive decline. The findings may help clinicians recognize and treat RPD earlier, enabling researchers to work from a shared framework when studying the condition.
Researchers found that mitochondrial RNA can leak into healthy tissue, triggering inflammation and scarring. Inhibiting certain proteins enables mitochondrial RNA to escape, leading to less inflammation and healthier liver tissue.
Researchers at Mayo Clinic have developed a smartwatch-based alert system that signals parents to intervene in children with emotional and behavioral disorders, reducing tantrum duration by an average of 11 minutes. The system uses physiological stress signals detected by the smartwatch to prompt parental intervention.
A new Mayo Clinic study found that an off-the-shelf dual-antibody therapy generates deep and durable responses in extramedullary multiple myeloma. In a trial of 90 patients, 79% responded to treatment, with nearly two-thirds maintaining disease control at one year.
A new study by Mayo Clinic researchers found that using digital check-ins and a remote care team can help patients manage symptoms before they reach a crisis point. The trial showed that the automated surveys and responses built into the electronic health record made care more efficient and improved patients' symptoms.
Researchers developed a new 3D surface scanning approach for precise brain surgery, outperforming CT scans in accuracy. The system eliminates radiation exposure and provides real-time guidance to surgeons.
Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors responding well to immunotherapy. The study identified markers that may predict a positive response to immunotherapy, including the presence of senescent tumor cells and loss of the PRKCI gene.
Researchers at Mayo Clinic have developed a new approach to treating drug-resistant epilepsy by mapping each patient's unique brain wave patterns. This method enables physicians to target the precise area in the brain where stimulation is most effective, moving beyond traditional one-size-fits-all treatment.
A Mayo Clinic study found that nearly 90% of people with the inherited condition familial hypercholesterolemia would not have been flagged for standard genetic testing. This condition can cause dangerously high cholesterol and early heart disease, making it highly treatable yet often undiagnosed.
Researchers create new prediction model combining age, sex, genetic risk, and brain amyloid levels to calculate lifetime risk of developing memory problems. The study, published in The Lancet Neurology, found women have a higher lifetime risk than men, with the common APOE ε4 variant increasing risk.
Researchers created an AI algorithm that can identify obstructive sleep apnea (OSA) using ECG test results, making it faster and cheaper to spot the condition. The innovation reveals a higher visibility of OSA on ECG in females compared to males, suggesting they may suffer more cardiovascular damage.
The new approach uses lab-grown heart tissue made from reprogrammed adult stem cells, delivered through a tiny incision. In preclinical testing, the stem cell patch restored heart function and improved healing, offering a new way to repair damaged hearts.
Mayo Clinic's new platform provides access to its data-driven expertise, clinical knowledge, and AI insights to healthcare organizations worldwide. The program helps navigate the complex AI landscape in healthcare and implement solutions to improve patient outcomes.
HealthLocator gathers national quality data to compare hospitals based on performance and provide informed care choices. The tool is offered as a free public service by Mayo Clinic, using evidence-based measures to rate over 5,000 U.S. hospitals.
Researchers at Mayo Clinic have found a way to enhance the body's 'first responder' cells, which can boost standard immunotherapies for cancer. By targeting these myeloid cells, it may be possible to improve treatments that interfere with immune suppressive proteins PD-1 and PD-L1.
A Mayo Clinic study of nearly 5,000 midlife women found that over three-quarters experienced menopause symptoms, yet only one in four received treatment. The study highlights the importance of healthcare professionals identifying and managing menopause symptoms to improve women's health and quality of life.
Researchers at Mayo Clinic have developed a new technique to identify senescent cells using aptamers, which can potentially lead to targeted therapies. The study found several rare aptamers that bind specifically to fibronectin on the surface of mouse cells, offering a promising approach for characterizing and treating senescent cells.
A new study led by Mayo Clinic researchers found that abemaciclib improves survival for people with high-risk, early-stage breast cancer. The drug reduced the risk of death by 15.8% compared to endocrine therapy alone among patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
A new genomic test can identify people with melanoma as being at low or high risk of cancer spreading to their lymph nodes. The test uses gene expression profiles from a tumor sample, eliminating the need for additional biopsies, and may help guide treatment decisions.
Researchers at the Mayo Clinic have found that platelet-rich plasma (PRP) treatment can significantly improve genitourinary syndrome of menopause (GSM) symptoms in breast cancer survivors. After six months, GSM symptoms such as sexual function, urinary symptoms and quality of life improved, even among those taking estrogen blockers.
Researchers discovered a molecular circuit controlling AT2 cell fate plasticity, which could guide regenerative therapies for chronic lung diseases. The discovery highlights potential new targets for regenerative medicine and may lead to earlier detection and prevention of organ failure.